Practice guidelines, expert recommendations, and FDA guidance documents.
On January 21, 2026, the FDA released draft guidance on using minimal residual disease and complete response in multiple myeloma to support accelerated approval, defining the MRD endpoint as bone-marrow negativity by flow cytometry or sequencing in patients who have achieved complete response or stringent complete response, and noting that the April 12, 2024 ODAC unanimously accepted MRD as an accelerated-approval endpoint.
Federal Register
A Blood Advances article dated March 25, 2025, reviews measurable residual disease in adult ALL and notes that blinatumomab is indicated for MRD-positive B-cell ALL and, on the basis of the E1910 overall-survival result, is also used in newly diagnosed Philadelphia-negative ALL regardless of MRD response.
Blood Advances
At the NCCN 2026 Annual Conference, faculty reported that ADT plus niraparib and abiraterone is listed for BRCA2-mutated metastatic androgen-pathway-sensitive prostate cancer, as useful in certain circumstances for high-volume disease and as a category 2B option for low-volume disease.
The ASCO Post
The NCCN 2026 prostate cancer update presented at the NCCN Annual Conference adds a table of FDA-cleared PET imaging tracer studies, in a discussion that noted prior registration trials used conventional imaging rather than PSMA PET.
The ASCO Post
The 2026 NCCN kidney cancer discussion added a recommendation, for non-clear-cell renal cell carcinoma, to consider tumor genomic testing for clinical-trial eligibility.
The ASCO Post
The ESMO clinical practice guideline on advanced and metastatic prostate cancer, approved by the ESMO Guidelines Committee in January 2026, recommends genomic testing for BRCA1, BRCA2, CDK12, and PALB2 in all patients with castration-resistant prostate cancer, ideally before the first treatment for metastatic CRPC.
Annals of Oncology
Faculty at the NCCN 2026 Annual Conference described a new prostate-guideline pathway for metastasis-directed therapy in metachronous oligometastatic androgen-pathway-sensitive disease, including metachronous low-volume M1 disease.
The ASCO Post
At the NCCN 2026 Annual Conference, faculty reported that ipilimumab plus nivolumab moved from category 2A to a category 1 preferred first-line regimen for clear-cell renal cell carcinoma.
The ASCO Post
Faculty at the NCCN 2026 Annual Conference said subsequent therapy for renal cell carcinoma now includes lenvatinib as a category 2A option in defined settings, while axitinib plus pembrolizumab, cabozantinib plus nivolumab, and lenvatinib plus pembrolizumab moved from category 2A to 2B, and axitinib plus avelumab was removed.
The ASCO Post
At the NCCN 2026 Annual Conference, enfortumab vedotin plus pembrolizumab was described as the sole preferred first-line regimen in the bladder cancer guideline for locally advanced or metastatic disease.
The ASCO Post
Faculty at the NCCN 2026 Annual Conference described perioperative durvalumab with gemcitabine and cisplatin as the preferred treatment for cisplatin-eligible muscle-invasive bladder cancer.
The ASCO Post